IND Readiness Diagnostic: 12 Questions Sponsors Should Answer Before Submitting

A Practical Framework to Assess IND Readiness Before Filing

Identify gaps early. Reduce FDA risk. Strengthen your submission strategy.

Preparing for an Investigational New Drug (IND) submission requires more than assembling documentation. It requires alignment across regulatory strategy, clinical planning, nonclinical support, and CMC readiness.

This white paper introduces a structured diagnostic framework to help sponsors evaluate IND readiness before submission and identify potential gaps that could delay FDA review.

Why Does IND Readiness Matter?

Gaps in IND readiness can result in:

• FDA information requests that delay timelines
• Clinical holds driven by safety or design concerns
• Misalignment with long-term development strategy
• Increased cost and rework

A proactive, structured approach to readiness helps ensure a more efficient review process and stronger development foundation.

What You'll Learn

This resource provides a practical approach to assessing IND readiness, including:

• The 12 key questions sponsors should answer before filing
• How FDA evaluates IND submissions across core disciplines
• Common gaps that lead to information requests or clinical holds
• Strategies to align regulatory, clinical, and CMC planning
• A framework to strengthen submission quality and readiness

Strengthen Your IND Strategy Before You Submit

An IND submission is a critical milestone, but the work that determines success happens before filing.

Download our IND Readiness Diagnostic today to assess your IND preparedness and identify potential gaps early.